Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNABW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ginkgo Bioworks Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ginkgo Bioworks Holdings's regulatory disclosures and financial reporting.
Ginkgo Bioworks Holdings director/officer Reshma P. Shetty exercised performance-based stock units and sold shares to cover taxes. On April 9, 2026, 251,786 performance-based restricted stock units vested and converted into Class A Common Stock based on a company-wide cash flow target achieved at 67% of goal.
These units came from a June 19, 2025 grant of 375,800 PSUs tied to cash flow performance for the period from January 1, 2025 to December 31, 2025. On April 10, 2026, 124,727 shares of Class A Common Stock were sold solely to satisfy tax withholding obligations under the company’s equity incentive plans through a required “sell to cover” transaction, which the disclosure states was not a discretionary trade. After these transactions, Shetty directly held 436,422 shares of Class A Common Stock.
Ginkgo Bioworks Holdings director/officer Reshma P. Shetty exercised performance-based stock units and sold shares to cover taxes. On April 9, 2026, 251,786 performance-based restricted stock units vested and converted into Class A Common Stock based on a company-wide cash flow target achieved at 67% of goal.
These units came from a June 19, 2025 grant of 375,800 PSUs tied to cash flow performance for the period from January 1, 2025 to December 31, 2025. On April 10, 2026, 124,727 shares of Class A Common Stock were sold solely to satisfy tax withholding obligations under the company’s equity incentive plans through a required “sell to cover” transaction, which the disclosure states was not a discretionary trade. After these transactions, Shetty directly held 436,422 shares of Class A Common Stock.
DNA submitted a Form 144 notice listing 33,171 shares of Class A stock associated with a restricted stock vesting event dated 04/10/2026. The filing lists Fidelity Brokerage Services LLC as a broker and records prior dispositions by Steve Coen of 972 and 708 shares on 01/20/2026 and 03/16/2026, respectively.
DNA submitted a Form 144 notice listing 33,171 shares of Class A stock associated with a restricted stock vesting event dated 04/10/2026. The filing lists Fidelity Brokerage Services LLC as a broker and records prior dispositions by Steve Coen of 972 and 708 shares on 01/20/2026 and 03/16/2026, respectively.
DNA filed a Form 144 reporting a proposed sale of Class A shares and recent small dispositions. The filing lists 40,893 Class A shares tied to a proposed sale and records two past dispositions of 2,200 shares on 02/04/2026 and 03/11/2026. The broker listed is Fidelity Brokerage Services LLC.
DNA filed a Form 144 reporting a proposed sale of Class A shares and recent small dispositions. The filing lists 40,893 Class A shares tied to a proposed sale and records two past dispositions of 2,200 shares on 02/04/2026 and 03/11/2026. The broker listed is Fidelity Brokerage Services LLC.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Filer reported sales of restricted Class A shares. The filing lists two recent dispositions by Bartholomew Canton: 13,155 shares on 04/08/2026 and 13,116 shares on 04/09/2026, with dollar amounts shown. The record also lists 124,727 shares associated with Fidelity Brokerage Services LLC and a total share figure of 49,941,878 as of 04/10/2026.
Filer reported sales of restricted Class A shares. The filing lists two recent dispositions by Bartholomew Canton: 13,155 shares on 04/08/2026 and 13,116 shares on 04/09/2026, with dollar amounts shown. The record also lists 124,727 shares associated with Fidelity Brokerage Services LLC and a total share figure of 49,941,878 as of 04/10/2026.
Issuer reported a Form 144 notice for the proposed sale of 13,116 Class A shares under Rule 144. The shares arose from Restricted Stock Vesting dated 04/08/2026 and are held at Fidelity Brokerage Services LLC.
The filing lists prior sales of 13,155 Class A shares by Bartholomew Canton on 04/08/2026 and shows 49,941,878 shares outstanding as of 04/09/2026.
Issuer reported a Form 144 notice for the proposed sale of 13,116 Class A shares under Rule 144. The shares arose from Restricted Stock Vesting dated 04/08/2026 and are held at Fidelity Brokerage Services LLC.
The filing lists prior sales of 13,155 Class A shares by Bartholomew Canton on 04/08/2026 and shows 49,941,878 shares outstanding as of 04/09/2026.
Jason Kelly reports a proposed sale of 109,767 shares of Class A common stock under Form 144. The securities are tied to restricted stock vesting as compensation and dated 04/08/2026. The filing shows 97,015 shares sold during the past three months, with values listed as $702,201.45 and $672,343.05. Trades are noted for the NYSE and the filing header date is 04/09/2026.
Jason Kelly reports a proposed sale of 109,767 shares of Class A common stock under Form 144. The securities are tied to restricted stock vesting as compensation and dated 04/08/2026. The filing shows 97,015 shares sold during the past three months, with values listed as $702,201.45 and $672,343.05. Trades are noted for the NYSE and the filing header date is 04/09/2026.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.